The present invention relates to processes of producing glutamic acid compounds, for example, monatin, which are useful as, for example, production intermediates for sweetener or pharmaceutical products.

The present invention is directed to certain hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

The present invention discloses novel dual prodrug compositions of Formula 1, ##STR00001## wherein A is a single bond, --O--, or --CH.sub.2--; m and n vary from 0 to 15; p and q vary from 0 to 4; B is a single bond or --CR.sup.3R.sup.4; D is selected from the group consisting --CO.sub.2R.sup.5, --OR.sup.6, --OCOR.sup.7, --SO.sub.3R.sup.8, --SO.sub.2NH.sub.2, --OPO(OR.sup.9)(OR.sup.10), --OPO(OR.sup.9)(NH.sub.2), --OPO(OR.sup.9)--O--PO(OR.sup.10)(OR.sup.11), ##STR00002## R.sup.1 to R.sup.11 are v...

A catalyst includes a cyclic imide compound having an N-substituted cyclic imide skeleton represented by following Formula (I): ##STR00001## wherein X is an oxygen atom or a hydroxyl group, and having a solubility parameter of less than or equal to 26 [(MPa).sup.1/2] as determined by Fedors method. The catalyst may further comprise a metallic compound. By allowing (A) a compound capable of forming a radical to react with (B) a radical scavenging compound in the presence of the catalyst, an addit...

A process is provided for the preparation of 9,10-dihydro-9-oxa-10-organylphosphaphenanthrene-10-oxide and derivatives of same substituted on the phenyl groups, in which: (a) 9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide (DOP) or a derivative of same is reacted in the presence of at least one mono- or polyhydric alcohol with at least one ortho ester with formation of a first intermediate product, (b) the intermediate product from step (a) is optionally reacted with at least one further mono...

A process is provided for the preparation of 9,10-dihydro-9-oxa-10-organyloxyphosphaphenanthrene-10-oxide or -thione and derivatives of same substituted on the phenyl groups, in which: (a) 9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide (DOP) or a derivative of same is reacted in the presence of at least one mono- or polyhydric alcohol with at least one ortho ester with formation of a first intermediate product, (b) the intermediate product from step (a) is optionally reacted with at least on...

A novel polymer-supported arene-ruthenium complex represented by the following formula: ##STR00001## , wherein A represents an organic polymer with a side chain containing an aromatic ring coordinated to Ru, X.sub.1 and X.sub.2 represent the same or different halogen atoms, and R represents a hydrocarbon group that may have a substituent is provided for use as a catalyst. This novel polymer-supported arene-ruthenium complex and catalyst thereof can be produced by a simple process, are stable and...

The present invention is concerned with compounds of formula ##STR00001## the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein R.sup.1 is hydrogen, hydroxy, C.sub.1-6alkyl or aryl; R.sup.2 is hydrogen; optionally substituted C.sub.1-12alkyl; C.sub.3-7cycloalkyl; C.sub.2-8alkenyl, optionally substituted pyrrolidinyl or aryl; R.sup.3 is hydrogen, optionally substituted C.sub.1-6alkyl or aryl; Het is an optionally substituted unsatura...

A compound of the invention is a specific compound having a phosphorylcholine group, and a polymer of the invention comprises at least 1 mol % of repeating units with a phosphorylcholine group and has a number-average molecular weight of 1,000 or more, the repeating units with a phosphorylcholine group being represented by the formula (II): ##STR00001## wherein A is a bond selected from a single bond, --O--, --COO--, --OOC--, --CONH--, --NH--, --NHCO--, --NR.sup.2-- and --CH.sub.2O-- where R.sup...

The present invention relates to phosphinic acid derivatives of formula I ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are described hereinabove. These compounds can be used in the treatment or prevention of a disease related to the inhibition of .beta.-secretase, inter alia for the treatment of Alzheimer's disease.